E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10053983 |
E.1.2 | Term | Corona virus infection |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe or critical COVID-19
|
|
E.2.2 | Secondary objectives of the trial |
Evaluate the 28-day survival rate,Evaluate the clinical efficacy of sarilumab compared to the control arm by clinical severity, changes in the National Early Warning Score 2, duration of predefined symptoms and signs, duration of supplemental oxygen dependency, incidence of new mechanical ventilation use, proportion of patients requiring rescue medication, need for admission into ICU, duration of hospitalization.
Secondary safety objectives are to evaluate the safety of sarilumab compared to the control arm as assessed by incidence of: SAEs, Major or opportunistic bacterial or fungal infections in patients with grade 4
neutropenia , Grade ≥2 infusion related reactions, Grade ≥2 hypersensitivity reactions, Increase in ALT ≥3X ULN (for patients with normal baseline) or >3X ULN and at least 2-fold increase from baseline value (for patients with abnormal baseline), Major or opportunistic bacterial or fungal infections. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Participants must be ≥18 years of age
Participants must be hospitalized for less than or equal to 7 days with
evidence of pneumonia and have one of the following disease categories:
severe disease or critical disease
Laboratory-confirmed SARS-CoV-2 infection |
|
E.4 | Principal exclusion criteria |
Unlikely to survive after 48 hours from screening or unlikely to remain at
the investigational site beyond 48 hours. Patients with multi organ dysfunction or requiring extracorporeal life support or renal replacement
therapy are excluded.
Presence of neutropenia less than 2000/mmˆ3, AST or ALT greater than
5 X ULN, platelets less than 50,000/mmˆ3
Prior immunosuppressive therapies
Use of chronic oral corticosteroids for non-COVID-19 related condition
Known or suspected history of tuberculosis
Suspected or known active systemic bacterial or fungal infections |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Time to improvement of 2 points in clinical status assessment from baseline using the 7-point ordinal scale |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1 - Percent of patients alive at Day 29
2 - Proportion of patients with one point improvement from baseline in
clinical status assessment at days 4, 7, 15, 21, 29 using the 7-point
ordinal scale
3 - Mean change in the 7-point ordinal scale from baseline to days 4, 7,
15, 21, and 29 (or until discharge)
4 - Time to resolution of fever
5 - Time to resolution of fever and improvement in oxygenation
6 - Days with fever
7 - Time to change in NEWS2 from baseline
8 - Time to NEWS2 of <2 and maintained for 24 hours
9 - Mean change from baseline to days 3, 5, 8, 11, 15, and 29 in NEWS2
10 - Time-to-improvement in oxygenation
11 - Alive off supplemental oxygen at day 29
12 - Days of hypoxemia
13 - Days of supplemental oxygen use
14 - Days of resting respiratory rate >24 breaths/min
15 - Time to saturation ≥94% on room air
16 - Ventilator free days in the first 28 days (to day 29)
17 - The number of patients with Initiation of mechanical ventilation,
non-invasive ventilation, or use of high flow nasal cannula
18 - Proportion of patients requiring rescue medication during the 28-
day period
19 - The number of patients transferred to the ICU or the need to
transfer to the ICU (if the ICU is not available)
20 - Days of hospitalization among survivors
21 - Incidence of serious adverse events
22 - The incidence of major or opportunistic bacterial or fungal infections
23 - The incidence of major or opportunistic bacterial or fungal infections
in patients with grade 4 neutropenia
24 - The incidence of hypersensitivity reactions, infusion reactions,
gastrointestinal perforation
25 - The number of patients with clinically significant laboratory
abnormalities. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1: Day 29
2-3, 9 : Baseline to Days 4, 7, 15, 21, 29
4-8, 10-16 : Baseline to Day 29
17, 19-24 : Baseline to Day 60
18 : Baseline to Day 28
25 : Days 1, 4,7,15, 21 and 29 (if still hospitalized) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 16 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
France |
Germany |
Israel |
Italy |
Japan |
Russian Federation |
Spain |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 14 |
E.8.9.2 | In all countries concerned by the trial months | 5 |
E.8.9.2 | In all countries concerned by the trial days | 15 |